Chemotherapy and NK Cell Infusion for Osteosarcoma

M D Anderson Cancer Center, Houston, TX
Osteosarcoma+2 More ConditionsCAR.70/IL15-transduced CB-derived NK cells - Drug
18 - 80
All Sexes
What conditions do you have?

Study Summary

This trial will test a therapy of donated NK cells & chemo for advanced kidney, lung, or bone cancer patients to find the best dose.

Eligible Conditions
  • Osteosarcoma
  • Mesothelioma
  • Kidney Cancer

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 1 & 2

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: through study completion; an average of 1 year.

Year 1
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

1 Treatment Group

Chemotherapy and NK Cell Infusion
1 of 1

Experimental Treatment

50 Total Participants · 1 Treatment Group

Primary Treatment: Chemotherapy and NK Cell Infusion · No Placebo Group · Phase 1 & 2

Chemotherapy and NK Cell InfusionExperimental Group · 3 Interventions: CAR.70/IL15-transduced CB-derived NK cells, Cyclophosphamide, Fludarabine phosphate · Intervention Types: Drug, Drug, Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Completed Phase 3
Fludarabine phosphate
Completed Phase 2

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: through study completion; an average of 1 year.

Who is running the clinical trial?

M.D. Anderson Cancer CenterLead Sponsor
2,849 Previous Clinical Trials
1,793,475 Total Patients Enrolled
14 Trials studying Osteosarcoma
522 Patients Enrolled for Osteosarcoma
David Hong, MDPrincipal InvestigatorM.D. Anderson Cancer Center
6 Previous Clinical Trials
280 Total Patients Enrolled

Eligibility Criteria

Age 18 - 80 · All Participants · 3 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Patients must meet specific requirements for their medical condition (see details below).
You must have finished any cell therapy for cancer at least 3 months ago.
You can have radiation to some areas before starting the study, but there must be other areas that haven't been treated with radiation that can be measured.

Frequently Asked Questions

Are individuals younger than 80 years of age permissible for this experiment?

"As detailed in the eligibility criteria, the patient population for this clinical trial consists of those aged 18 to 80. For patients under 18 and over 65 there are 177 trials and 2,649 trials respectively available." - Anonymous Online Contributor

Unverified Answer

Are patients able to participate in this research at present?

"As per information on, this study began recruitment on March 1st 2023 and ceased accepting patients as of January 27th 2023. Although this trial is not accepting applicants currently, there are 2,735 other studies open for enrollment at the moment." - Anonymous Online Contributor

Unverified Answer

What eligibility criteria must potential participants satisfy to take part in the medical research?

"This medical trial is presently looking for 50 individuals aged between 18 and 80 that are experiencing kidney cancer. Moreover, these patients must meet the following conditions: have given their informed consent to long-term follow up on protocol PA17-0483, possess advanced clear cell renal carcinoma, osteosarcoma or mesothelioma with CD70 expression of 10% in pre-enrollment tumor sample via immunohistochemistry or flow cytometry; fulfil disease specific criteria (see below); be at least 2 weeks from last chemotherapy before lymphodepleting chemotherapy procedure; haven't had any cell therapy for malignancy within" - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.